Clinical Trial Update: GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating GB491 in combination with fulvestrant for HR-positive, HER2-negative locally advanced or metastatic breast cancer has completed. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• GB491

Snippet

Sponsor: Genor Biopharma Co., Ltd. | Conditions: Locally Advanced or Metastatic Breast Cancer | Phase 3 | Status: COMPLETED